Preliminary analysis of immune responses in patients enrolled in a Phase II trial of cyclophosphamide with allogenic dribble vaccine alone (DPV-001) or with GM-CSF or imiquimod for adjuvant treatment of stage IIIa or IIIb NSCLC. Issue 2 (December 2015) - Sanborn, Rachel; Boulmay, Brian; Li, Rui; Spieler, Bradley; Happel, Kyle; Paustian, Christopher; Mougdil, Tarsem; Feng, Zipei; Dubay, Christopher; Fisher, Brenda; Koguchi, Yoshinobu; Aung, Sandra; et al.